Press releases
- InDex Pharmaceuticals Holding AB (publ) interim report January – September 201819 November 2018
- InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2019 Annual General Meeting06 November 2018
- InDex Pharmaceuticals carries out a directed share issue of approximately SEK 37.5 million23 October 2018
Cobitolimod
Cobitolimod (Kappaproct, DIMS0150) is a potential new medication for patients with moderate to severe active ulcerative colitis.
Cobitolimod is a first in class treatment that provides a local anti-inflammatory effect which in clinical trials has shown to result in significant improvements of the major clinical symptoms.
Cobitolimod has very limited systemic absorption. This gives the drug a favorable safety profile, in sharp contrast to many approved treatments.
Learn moreCalender
- 20 February 2019Year-end Report 2018
- 6 May 2019Interim Report Q1 2019
- 6 May 2019Annual General Meeting 2019
- 22 August 2019Interim Report Q2 2019
- 27 November 2019Interim Report Q3 2019
